IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.80+0.02 (+0.05%)
Close on Nov 13, 2026Market cap $40.48MP/E –Yield –
IRulya Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
IRulya Therapeutics's enterprise value was -$77.02M on Nov 11, 2026, against $3.97B a year earlier. Over the last 5 years it ranged from -$84.46M to $7.42B, with a median of $864.19M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$77.02M | -102.1% |
| 2025 | Dec 31, 2025 | $3.64B | +131.9% |
| 2024 | Dec 31, 2024 | $1.57B | +131.0% |
| 2023 | Dec 29, 2023 | $680.02M | +85.7% |
| 2022 | Dec 30, 2022 | $366.29M | -95.1% |
| 2021 | Dec 31, 2021 | $7.42B | -54.3% |
| 2020 | Dec 31, 2020 | $16.25B | -45.9% |
| 2019 | Dec 31, 2019 | $30.02B | – |
See a number that looks wrong?